2024 Scrip Asia 100
Latest Updates And Considerations In Asia Pacific
Korea is ranked higher for global clinical trials than ever before, Chinese regulators emphasize the need for patient centricity in trial design and decentralized clinical trials (DCTs) continue to transform the global clinical research environment.
The current status of decentralized clinical trials in Korea and the country’s efforts to boost activity in this area were discussed at the recent Bio Korea meeting, with cultural and medical practices, along with technological and medical literacy, among the areas seen as affecting broader adoption of the various elements of the approach.
The Pink Sheet takes an infographic look at South Korea's clinical trial trends in 2022 to illustrate how the country's biopharma R&D is developing and how activities are recovering in the post-pandemic situation. One key takeaway is that approvals for trial starts have fallen back to pre-COVID levels, suggesting a falling off of activity related to drugs and vaccines for the virus.
China's Center for Drug Evaluation has finalized new guidelines that stipulate sponsors of randomized controlled clinical studies should more closely consider patient needs and experience when designing trials, including a consideration of likely future changes in standard therapies.
